Last updated on March 2019

Alzheimer's Disease Research Study

Brief description of study

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 104. Participants will then be offered to enter into an open-label extension (OLE).

Clinical Study Identifier: TX218086

Find a site near you

Start Over

Meridien Research - Tampa

5411 Beaumont Center Boulevard #760 Tampa, FL United States
  Connect »